甲磺酸培高利特治疗帕金森病临床观察

应用国产甲磺酸培高利特片，采用随机双盲对照方法，对６１例帕金森病患者进行６周治疗。结果显示，治疗组的有效率明显高于对照组，不良反应小，值得推广。     

甲磺酸培高利特治疗原发性帕金森病

采用随机双盲给药观察６０例帕金森病患者，其中培高利特治疗组３０例，安慰剂对照组３０例，开放给药组６５例结果显示：治疗组及开放给药组与安慰剂组疗效有差异，具有统计学意义。开放受试药组治疗前后功能缺评分对照有显著差异，副作用的发生率仅为９．２３％，对肝肾功能无损害，对血象及心脏功能亦无影响。     

新多巴胺受体激动剂甲磺酸培高利特

目的：简述甲磺酸培高利特的药理活性和临床疗效。方法：临床前药理研究主要与溴隐亭进行比较。Ｉ期临床：对７例健康自愿受试者耐受性和血催乳素作用进行研究。临床试验：２６２例帕金森患者合并美多巴用药６周；１３５例高催乳素患者用药３周与溴隐亭比较。结果：药理评价显示甲磺酸培高利特是一典型Ｄ受体激动剂。帕金森病治疗，随机双盲临床试验显示合用美多巴比安慰剂合用美多巴更为有效（Ｐ〈０．０１）；治疗高催乳素血症显示     

新型抗帕金森病药：甲磺酸培高利特

甲磺酸培高利特 (协良行 )是多巴胺受体激动药 ,主要用于帕金森病 ,现将其药理作用与临床应用分述如下。1　药理作用1.1　药效学　本品是一种多巴胺Ｄ1、Ｄ2 双受体激动药。对多巴胺受体有高亲和性 ,直接刺激黑质和纹状体系统突触后神经的多巴胺Ｄ1和Ｄ2 受体。可明显减少帕金森病患者对天然多巴胺及左旋多巴的需要量。因此甲磺酸培高利特可有效控制帕金森病症状的同时 ,减少引起帕金森病恶化的氧自由基的合成。作用强 ,约比溴隐亭大 10倍。作用时间长 ,对帕金森病作用可维持 6ｈ。此外 ,本品还能抑制泌乳素和生长激素的分泌。降低泌乳素的…     

甲磺酸培多利特联合左旋多巴治疗帕金森病效果分析

应用甲磺酸培多利特(协良行)合并左旋多巴治疗帕金森氏病的临床及主要副作用进行系统观察。     

进口与国产培高利特治疗帕金森病的疗效比较

目的 :比较进口与国产培高利特治疗帕金森病的疗效。方法 :在并用 (进口组有 6例不并用 )左旋多巴 苄丝肼下 ,进口组帕金森病 68例 ,男性 35例 ,女性 33例 ,年龄 64a±s 12a ,给进口培高利特从 0 .0 2 5mg·d- 1开始 ;国产组 70例 ,男性 37例 ,女性 33例 ,年龄 64a± 9a ,给国产培高利特从 0 .0 5mg·d- 1开始 ,均逐渐增至 0 .5～ 0 .75mg·d- 1,于 3mo后评定疗效。结果 :进口组总有效率 91% ,运动波动总有效率 94 % ,平均每例左旋多巴 苄丝肼剂量减少 2 8% ,国产组分别为 4 6% ,35% ,8%。差异有非常显著意义 (P <0 .0 1)。进口组副作用略多于国产组。结论 :进口培高利特治疗帕金森病效果优于国产品 ,副作用较国产培高利特略明显。     

培高利特治疗超老年帕金森病10例

目的:观察培高利特治疗超老年帕金森病(PD)的疗效与副作用.方法:采用回顾性分析,10例超老年PD患者在维持原治疗的基础上加用培高利特25～50 μg&#8226;d 1,分2或3次,po,疗程1.5～60个月.结果:8例用该药有效,有效率80.0%,维持量250～750 μg&#8226;d 1,4例有轻微不良反应,便秘常见.结论:用培高利特治疗超老年PD,耐受性较好,可与苯海索、金刚烷胺、左旋多巴合用,并能增加疗效.     

甲磺酸培高利特片溶出度的测定

采用小杯法溶出继以ＨＰＬＣ法检测，建立了甲磺酸培高利特片的溶出度测定方法，平均回收率为９９．７８％，ＲＳＤ为１．６２％。     

普拉克索联合左旋多巴治疗帕金森病的临床疗效及安全性

目的 探讨左旋多巴联合普拉克索治疗帕金森病的临床疗效及安全性。方法 选取2015年8月—2017年12月于南通市第一人民医院神经内科门诊或住院诊治的帕金森病患者150例,采用随机法分为观察组（80例）和对照组（70例）,对照组患者仅给予左旋多巴进行治疗,观察组患者给予左旋多巴联合普拉克索进行治疗,持续服药12周,比较两组患者帕金森病综合评估量表（UPDRS）Ⅱ和UPDRS Ⅲ、汉密顿抑郁量表（HAMD）及不良反应的发生率。结果 治疗前,两组患者的UPDRS Ⅱ和UPDRS Ⅲ评分相比,差异无统计学意义;经治疗后,两组患者UPDRS Ⅱ和UPDRS Ⅲ评分均显著降低,同组治疗前后比较差异有统计学意义（P<0.05）;与对照组相比,观察组患者UPDRS Ⅱ和UPDRS Ⅲ评分显著低于对照组,差异有统计学意义（P<0.05）。治疗后,两组患者的HAMD评分显著降低,同组治疗前后比较差异有统计学意义（P<0.05）;与对照组治疗后相比,观察组患者的HAMD评分显著降低,差异具有统计学意义（P<0.05）。观察组患者不良反应发生率为13例（16.25%）,对照组患者不良反应发生率为9例（12.86%）,差异无统计学意义。结论 左旋多巴联合普拉克索治疗帕金森病的临床疗效较好,且安全可靠。     

复方阿嗪米特联合莫沙必利治疗功能性消化不良的效果及安全性评价

目的探讨复方阿嗪米特联合莫沙必利治疗功能性消化不良的效果及安全性。方法选取2016年4月~2018年9月期间200例功能性消化不良患者,分为观察组与对照组,每组各100例。将单纯采用莫沙必利治疗的患者纳入对照组,联合复方阿嗪米特治疗的患者纳入观察组,对比两组患者临床疗效及不良症状的积分情况。结果观察组的治疗有效率98.00%比对照组的治疗有效率88.00%显著提升(P<0.05);治疗后两组患者的TESS评分明显下降,且观察组TESS评分明显低于对照组(P<0.05)。结论功能性消化不良患者使用复方阿嗪米特联合莫沙必利治疗成效显著,不良症状少。     

Multitemperature stability and degradation characteristics of pergolide mesylate oral liquid

The stability of pergolide mesylate in an oral aqueous liquid was studied. Stability and solubility data were used to determine the degradation characteristics of the drug in this formulation. Samples were stored in the dark at 35°C, 45°C, and 60°C. At 1, 2, 4, 8, 12, and 16 weeks, samples were removed and stored in a -80°C freezer for high performance liquid chromatography (HPLC) assay at a later date. The initial drug concentration of 0.30 mg/mL was determined by assay after storage at -80°C. A solubility of 6.9 mg/mL was found for pergolide mesylate in the oral liquid at room temperature with a relative standard deviation (RSD) of 4.0%. The degradation process is considered first-order at 25°C and 35°C. At higher temperatures (45°C and 60°C), a color change and curvature at the latter time points in degradation profiles are ascribed to the presence of methylcellulose. The activation energy calculated for degradation of pergolide mesylate in the oral liquid was 21.3 kcal/mol. The time to reach 90% potency (t90) values were calculated to be 43 days and 3 days, respectively, for storage at 25°C and 35°C. Drug concentrations up to ~6 mg/mL can be maintained as a solution at room temperature with this formulation.     

肝动脉化疗栓塞术序贯甲磺酸阿帕替尼治疗晚期肝门部胆管癌的有效性和安全性

目的 探讨肝动脉化疗栓塞术（TACE）序贯甲磺酸阿帕替尼治疗晚期肝门部胆管癌（HCCA）的有效性和安全性。方法回顾性分析成都市第三人民医院2017年6月至2020年6月收治的50例晚期HCCA病人的临床资料,依据治疗方案的不同分为两组,A组（n=24）给予经皮肝胆道支架置入术,B组（n=26）在经皮肝胆道支架置入术后给予TACE序贯甲磺酸阿帕替尼治疗。对比两组疗效、生存情况、不良反应,检测血清γ-谷氨酰转肽酶（γ-GT）、总胆红素（TBIL）、丙氨酸氨基转移酶（ALT）水平。结果 B组客观缓解率61.54%高于A组33.33%(P<0.05)。治疗后两组血清γ-GT、TBIL、ALT水平均低于治疗前（P<0.05）,且治疗后B组血清γ-GT、TBIL、ALT水平均低于A组（P<0.05）。B组6个月生存率、1年生存率均高于A组（P<0.05）。两组组间不良反应发生率比较差异无统计学意义（P>0.05）。结论 TACE序贯甲磺酸阿帕替尼治疗晚期HCCA疗效确切,能延长病人生存时间,利于改善病人肝功能,且未增加不良反应发生。     

贝那普利单用及其与乐卡地平联用的临床疗效及安全性观察

目的 评估贝那普利单用及其与乐卡地平联用治疗原发性轻中度高血压的疗效和安全性.方法 入选本研究的原发性轻中度高血压患者138例,经4周贝那普利10 mg单药治疗后坐位舒张压(SeDBP)≥90 mmHg的患者89例,随机分为贝那普利10 mg联合乐卡地平10 mg治疗(A组)和贝那普利20 mg单药治疗(B组),治疗4...     

Behavioral effects of pergolide mesylate on food intake and body weight

In a crossover design experiment, pergolide mesylate significantly suppressed food intake and body weight in spayed female rats. Inhibition of food intake by a constant dose of pergolide progressively diminished with repeated administrations. Pergolide continued to suppress body weight with no indications of tolerance. When pergolide was discontinued, body weight increased sufficiently to compensate for the loss and failure to gain during drug treatment. A second experiment investigated the observation that animals injected first with vehicle showed greater anorexia when subsequently injected with pergolide than did animals injected first with pergolide. In addition, tolerance was further assessed by administering on two occasions a higher dose of pergolide. Following chronic pergolide treatment, this dose was insufficient to reinstate anorexia; however, after a period of abstinence, this dose produced anorexia comparable to that observed at the beginning of pergolide treatment. Due to pergolide mesylate's action as a postsynaptic dopamine agonist, a dopaminergic neural system is implicated in pergolide induced anorexia.     

联合应用复方左旋多巴制剂致睡眠异常1例

1例慢性肾脏病(CKD)87岁男性患者因帕金森病服用卡左双多巴控释片(每片含卡比多巴50 mg、左旋多巴200 mg)半片、tid,治疗超过2年。1周前因精神症状加重,加用多巴丝肼(每片含左旋多巴200 mg、苄丝胼50 mg)半片、qid,治疗12 d后出现嗜睡、呼之不醒。停用卡左双多巴控释片后患者自行清醒,且未再发生睡眠发作。     

阿维A联合复方氟米松软膏外用治疗寻常型银屑病的疗效观察

目的观察阿维A联合复方氟米松软膏外用对治疗寻常型银屑病的临床疗效及安全性。方法选择我科收治的80例寻常型银屑病患者,随机分为治疗组和对照组各40例,治疗组给予口服阿维A胶囊联合外用复方氟米松软膏,对照组仅给予口服阿维A胶囊,疗程均为6周。以银屑病的皮损面积和严重程度(PASI)对两组患者进行疗效评价,同时观察两组患者治疗过程中出现的不良反应。结果治疗第6周时治疗组和对照组的有效率分别为87.5%和67.5%,差异有统计学意义(P<0.05);第6周时治疗组的PASI评分(3.03±1.53)明显低于对照组(5.86±2.36),差异有统计学意义(P<0.05)。个别患者在用药过程中出现的不良反应有血脂轻度升高、口唇干、皮肤干燥,症状均较轻微。结论阿维A联合复方氟米松软膏外用对治疗寻常型银屑病疗效确切,安全性高。     

国产复方非洛地平缓释片治疗原发性高血压的疗效和安全性

目的 评价国产复方非洛地平缓释片治疗轻、中度原发性高血压的疗效和安全性.方法 采用多中心、随机、双盲双模拟、前瞻性平行对照方法,从321例高血压患者中筛选出经非洛地平(5mg)单药治疗4wk、血压不能满意控制者217例,随机分为试验组和对照组,继续治疗8wk,分别服用复方非洛地平缓释片(由马来酸依那普利和缓释非洛地平组成,5mg/5mg)1片和非洛地平缓释片(5mg)、马来酸依那普利片(5mg)各1片.双盲治疗4wk后DBP不低于90mm Hg(1mm Hg=0.133kPa)者剂量加倍.结果 前4wk非洛地平单药治疗的有效率32.4%,降压无效而人组者血压平均下降(5.4±3.3/2.7±1.9)mm Hg.后8wk联合用药降压的总有效率试验组和对照组分别为88.3%和92.2%,血压分别进一步下降16.2/10.5mm Hg和14.8/11.4mm Hg.单药的不良反应主要为头痛、头晕、头胀、面部潮红等(12.0%).双盲试验期不良反应总发生率试验组和对照组分别为19.4%和14.7%,其中干咳发生率分别占6.5%和8.3%.结论 国产复方非洛地平缓释片治疗轻、中度原发性高血压安全、有效.     

Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting

OBJECTIVE: To evaluate the short- and long-term efficacy and safety of abciximab and cilostazol in patients with acute MI and unstable angina undergoing intracoronary stenting. METHODS: Acute-phase (7 and 30 days), 6-month and long-term composite outcomes involving death, myocardial infarction or urgent target vessel revascularization (TVR) together with other outcomes (composite outcomes involving death, MI and elective TVR with restenosis and stroke) were evaluated retrospectively in a total of 175 patients. Safety outcomes were assessed using data on the incidence of bleeding and thrombocytopenia at Day 7 and Day 30. RESULTS: Of 175 patients, 83 (47.4%) patients received abciximab. At 7 and 30 days, the composite outcome for the group treated with cilostazol alone and that treated with abciximab in combination with cilostazol did not differ significantly. The composite outcomes at 6 months and 1 year were significantly lower in the abciximab plus cilostazol group (relative risk 0.35, 95% Cl 0.13 - 0.90, relative risk 0.28, 95% CI 0.10 -0.78, respectively). The incidence of major bleeding at the access-site and in the gastrointestinal tract and minor bleeding were significantly higher in the group receiving abciximab plus cilostazol group at 7 days (relative risk 3.33, 95% CI 1.66 - 6.65, relative risk 9.98, 95% CI 1.29 - 77.07, relative risk 1.96, 95% CI 1.06 - 3.62, respectively) and at 30 days (relative risk 3.33, 95% CI 1.66 - 6.65, relative risk 5.54, 95% CI 1.25 - 24.56, relative risk 1.96, 95% CI 1.06 - 3.62, respectively). CONCLUSION: The combination of abciximab and cilostazol showed an improvement in major cardiac incidents at 6 months and 1 year of the treatment when compared to the group receiving cilostazol alone. However, abciximab did not improve the incidence of death but increased the risk of bleeding complications.